Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA notices worth Rs...

    NPPA notices worth Rs 101 crore sent to Biocon, Lupin, Dr Reddys, others for skipping regulatory nod-Minister 

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-24T12:16:22+05:30  |  Updated On 16 Aug 2021 11:29 AM IST

    NPPA has so far issued demand notices for an amount of Rs 101 crore against defaulting companies. Out of this, an amount of Rs 5.56 crore has been recovered and demand notices amounting to Rs 89.31 crore are under litigation, Gowda said.


    New Delhi: The government has issued notices to pharma firms including Cipla, Dr Reddy's, Biocon, Lupin, Alembic Pharma, and Sanofi India, for introducing drugs without prior approval from the national drug pricing regulator, Parliament was informed on Tuesday.


    "Companies that introduced a total of 22 drugs "without prior approval of the National Pharmaceutical Pricing Authority (NPPA) have been issued notices," Minister for the Chemicals & Fertilizers, D V Sadananda Gowda said in a written reply in the Lok Sabha.


    The drugs include those used for treating conditions such as diabetes, inflammation and chronic hepatitis C among others.


    While Alembic Pharmaceuticals has introduced two drugs -- Resync 75/50 mg and Trivogo tablet without a prior nod from NPPA, Biocon has introduced Blisto Trio 0.2/500/2 mg and Blisto Trio 0.2/500/1 mg, he said.


    Cipla has introduced Hepcvel tablets and Dr Reddy's Laboratories has introduced Resof total 400/100 mg, without taking the prior permission, Gowda said.


    Eris Sciences has introduced Cyblex MV 80.3, Cyblex M 30, Cyblex M 60, Cyblex MV 80.2, Cyblex M 80, Cyblex M 40 without taking prior permission from the NPPA, he added.


    The other companies who launched the drugs without getting the prior nod from the national pharmaceutical pricing authority include -- Lupin, Sanofi India Ltd, Hetero Healthcare, Cadila Healthcare, Ipca Laboratories, Boehringer Ingelheim India and Kemwell Biopharma, Unichem Laboratories, Wockhardt and Medibios Laboratories, the minister said.


    Also Read: NPPA regulatory measures primarily triggered tough days for hospital sector, says Icra


    "The NPPA regularly takes action against such companies as per provisions of the Drugs (Prices Control) Order, 2013 (DPCO) which has been issued under the Essential Commodities Act, 1955," he added.


    NPPA has so far issued demand notices for an amount of Rs 101 crore against defaulting companies. Out of this, an amount of Rs 5.56 crore has been recovered and demand notices amounting to Rs 89.31 crore are under litigation, Gowda said.


    "Cases of new drugs are identified from the market-based data being referred to by the NPPA. In addition, new drug cases are also identified through complaint or information received from other sources," he added.


    Also Read: NPPA fixes retail price of 9 combo drugs including Metformin, Paracetamol; Details

    Alembic PharmaBioconBlisto TrioBoehringer IngelheimCadila Healthcarechronic hepatitis CCiplacyblexD V Sadananda GowdaDPCODr ReddyEris SciencesGovtHepcvelHepcvel tabletsHetero HealthcareIPCA LaboratoriesKemwell Biopharma.Unichem LaboratoriesLok SabhaLupinMedibios LaboratoriesMinister for the Chemicals & FertilizersNational Pharmaceutical Pricing AuthorityNPPApharmapharma companypharma newspharma news indiaResyncSanofi IndiaTrivogoWockhardt
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok